NASDAQ:SPRC SciSparc (SPRC) Stock Price, News & Analysis $6.82 +0.31 (+4.74%) Closing price 07/3/2025 03:38 PM EasternExtended Trading$7.00 +0.17 (+2.55%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SciSparc Stock (NASDAQ:SPRC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SciSparc alerts:Sign Up Key Stats Today's Range$6.12▼$7.2750-Day Range$5.75▼$8.4052-Week Range$4.14▼$37.59Volume123,237 shsAverage Volume198,834 shsMarket Capitalization$3.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Read More SciSparc Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreSPRC MarketRank™: SciSparc scored higher than 10% of companies evaluated by MarketBeat, and ranked 2698th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for SciSparc. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioSciSparc has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.66% of the float of SciSparc has been sold short.Short Interest Ratio / Days to CoverSciSparc has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SciSparc has recently decreased by 46.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSciSparc does not currently pay a dividend.Dividend GrowthSciSparc does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.66% of the float of SciSparc has been sold short.Short Interest Ratio / Days to CoverSciSparc has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SciSparc has recently decreased by 46.62%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for SciSparc this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SciSparc insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of SciSparc is held by insiders.Percentage Held by InstitutionsOnly 25.06% of the stock of SciSparc is held by institutions.Read more about SciSparc's insider trading history. Receive SPRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRC Stock News HeadlinesSciSparc Announces 1-for-21 Reverse Share Split - MorningstarJune 26, 2025 | morningstar.comMSciSparc Ltd. Adjourns Annual Meeting Due to Lack of QuorumJune 25, 2025 | msn.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 4 at 2:00 AM | Crypto Swap Profits (Ad)SciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share SplitJune 25, 2025 | finanznachrichten.deSciSparc Ltd. Announces One-for-Twenty One Reverse Share Split Effective July 3, 2025June 24, 2025 | quiverquant.comQSciSparc Announces 1-for-21 Reverse Share SplitJune 24, 2025 | globenewswire.comSciSparc secures Japanese patent for pain relief comboMay 28, 2025 | investing.comSciSparc Unveils Japanese Patent for Novel Pain Relief CombinationMay 27, 2025 | tipranks.comSee More Headlines SPRC Stock Analysis - Frequently Asked Questions How have SPRC shares performed this year? SciSparc's stock was trading at $7.56 at the beginning of 2025. Since then, SPRC shares have decreased by 9.7% and is now trading at $6.8250. When did SciSparc's stock split? SciSparc's stock reverse split before market open on Thursday, July 3rd 2025.The 1-21 reverse split was announced on Tuesday, June 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of SciSparc? Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SciSparc own? Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), Mullen Automotive (MULN), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT). Company Calendar Today7/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRC CIK1611746 Webscisparc.com Phone972-3717-5777FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.36 Quick Ratio5.28 Sales & Book Value Annual Sales$1.31 million Price / Sales58.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book7.94Miscellaneous Outstanding Shares11,226,000Free Float11,055,000Market Cap$76.62 million OptionableNot Optionable Beta0.72 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:SPRC) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.